U.S. Bank National Ass'n v. Angeion Corp.

615 N.W.2d 425, 2000 Minn. App. LEXIS 859, 2000 WL 1146245
CourtCourt of Appeals of Minnesota
DecidedAugust 15, 2000
DocketC3-99-2080, C7-00-386
StatusPublished
Cited by9 cases

This text of 615 N.W.2d 425 (U.S. Bank National Ass'n v. Angeion Corp.) is published on Counsel Stack Legal Research, covering Court of Appeals of Minnesota primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
U.S. Bank National Ass'n v. Angeion Corp., 615 N.W.2d 425, 2000 Minn. App. LEXIS 859, 2000 WL 1146245 (Mich. Ct. App. 2000).

Opinion

OPINION

LANSING, Judge.

This litigation involves the interpretation of an indenture. U.S. Bank, as trustee for Angeion Corporation noteholders, sued Angeion for defaulting on its obligation to make a repurchase offer to noteholders when it “conveyed, transferred, or leased all or substantially all of its assets or for injunctive relief.” On cross-motions for summary judgment, Angeion disputed that its sale and license of patents triggered the repurchase obligation. The district court agreed and granted summary judgment for Angeion. Because we conclude that the sale and license of patents constitutes an asset transfer within the meaning of the indenture, we hold that U.S. Bank has raised genuine issues of material fact on its claim for breach of the indenture and that summary judgment was premature. We reverse and remand for further discovery. But because U.S. Bank has not demonstrated that it lacks an adequate legal remedy or that it will suffer irreparable harm, we affirm the district court’s obder denying U.S. Bank’s temporary injunctive relief.

FACTS

Angeion incorporated in 1986 to develop, manufacture, and sell medical products. Initially, Angeion used its engineering and manufacturing technologies to custom design and manufacture products to customers’ specifications and devoted its research and development capabilities to designing proprietary products. In 1990, Angeion created a subsidiary to oversee intensified research into the development of laser catheter-ablation systems. The same year, Angeion acquired a company engaged in the development of implantable-cardioverter-defibrillator (ICD) systems.

Angeion sold its medical-accessory-products division in 1992 and focused its efforts on the development and production of the catheter-ablation and ICD systems. In 1997, Angeion entered into a joint venture with Synthelabo, a French pharmaceutical company, and its subsidiary, ELA Medical. In its 1998 annual-10-K report filed with the SEC, Angeion described itself as a company that designed, developed, and marketed ICDs and developed catheter-ablation technologies. Angeion ultimately developed a portfolio of about 150 patents and patent applications, including 99 U.S.issued patents, 8 approved-but-not-yet-issued U.S. patents, and 17 pending patent applications. Through its own portfolio and through cross-licensing, Angeion had access to more than 1,000 patents.

In 1996, Angeion sued CPI and its subsidiary, Guidant, Inc., for infringing four of Angeion’s ICD patents. CPI sued An-geion in September 1998 for infringement of several of its ICD patents.

In March 1998, Angeion issued a private-placement memorandum seeking sophisticated investors to buy the unsecured convertible notes that are at the base of this litigation. In April 1998, Angeion en *428 tered into an indenture with U.S. Bank as trustee for noteholders who purchased An-geion’s convertible notes in a private-placement offering. Angeion raised $22,150,000 through the 7½% convertible notes due, in 2003.

The placement memorandum incorporated Angeion’s 10-K for the fiscal year ending December 31, 1997, as well as recent quarterly reports and other documents filed with the SEC. The memorandum described Angeion as a company that designed, developed, manufactured, and marketed ICDs. The memorandum also disclosed risks of investment, including* Angeion’s continuing failure to make ■ a profit, the uncertainty of FDA approval-for its products, the need for additional financing, the impact of tough competition in the ICD market, the-importance of intellectual-property protection, and the uncertain results of the patent litigation with CPI.

In September 1998, Angeion entered an agreement with Cordis Webster, under which it transferred to Cordis Webster a small number of U.S. patents, U.S. pending patent applications, and patent applications. All of the patents and applications dealt with catheter-ablation technology. In exchange, Angeion received cash, future royalties, and funding for continued research in the catheter-ablation field.

In January 1999, Angeion reduced its workforce by 20%, iiicluding a 40% reduction of senior management. Angeion took the action to reduce its $2.5 million monthly cash “burn rate.” *

On April 8, 1999, Angeion announced its intention to “limit its participation in the ICD marketplace in order to redeploy its resources toward opportunities which may result in greater shareholder value.” An-geion stated it would “continue to explore strategic alternatives for the Company including potential license or sale of its assets.” In connection with its withdrawal from the ICD market, Angeion reduced its workforce by another 75%, retaining only employees needed for ongoing operations and to meet existing ICD obligations.

That same day, Angeion announced a settlement of the CPI patent litigation. Under the terms of the settlement, CPI paid $35 million for past infringement and future licensing. Angeion granted CPI nonexclusive licenses for all of its ICD patents. CPI agreed not to sue Angeion for certain of its ICD product lines, and, in return, Angeion agreed to pay royalties for use of patents licensed to CPI.

On May 12,1999, Angeion announced its withdrawal from its joint venture with ELA Medical. ELA Medical continued to distribute Angeion’s products under a supply agreement.

■ In June 1999, U.S. Bank received a letter from one of the noteholders, alleging that Angeion was in default on the indenture because it had sold all or substantially all of its assets and had failed to make a repurchase offer. U.S. Bank sent a letter to Angeion inquiring about the status of the company and warning that it may be in default. In August 1999, U.S. Bank sent a notice of default to Angeion; Angeion denied that it had defaulted.

On September 17, 1999, Angeion announced its intention to grant Medtronic a non-exclusive license to all of its ICD patents and patent applications for $9 million. On September 23, 1999, Angeion announced its intention to acquire all outstanding shares of Medical Graphics, Inc., a cardiopulmonary medical-device company, for $16.3 million in cash.

On September 24, 1999, U.S. Bank filed suit in district court, alleging that Angeion was in default on the indenture because it had sold all or substantially all of its assets and had not made a repurchase offer. U.S. Bank sought specific performance, equitable relief, declaratory judgment, imposition of a constructive trust, and damages. U.S. Bank then moved for a temporary injunction preventing Angeion from depleting its cash reserves. Angeion counterclaimed, alleging, among other things, breach of contract and interference with prospective economic advantage.

The district court denied U.S. Bank’s temporary-injunction motion, reasoning *429 that the balance of harm weighed against granting the injunction. Angeion then moved for summary judgment on all of U.S. Bank’s claims. In turn, U.S. Bank moved for summary judgment on An-geion’s counterclaims, and served interrogatories on Angeion. Angeion refused to answer the interrogatories, asserting that U.S. Bank’s motion for summary judgment evidenced a concession that there were no material issues of fact and obviated further discovery. On February 9, 2000, U.S. Bank noticed a motion to compel discovery and Angeion noticed a motion for a protective order.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
615 N.W.2d 425, 2000 Minn. App. LEXIS 859, 2000 WL 1146245, Counsel Stack Legal Research, https://law.counselstack.com/opinion/us-bank-national-assn-v-angeion-corp-minnctapp-2000.